Welcome to our dedicated page for ClearSign Technologies SEC filings (Ticker: CLIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ClearSign Technologies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ClearSign Technologies's regulatory disclosures and financial reporting.
ClearSign Technologies is asking stockholders to approve a reverse stock split and a related adjournment authority at a virtual special meeting on February 26, 2026. The board could combine every 2 to 10 existing shares of common stock into one share, at a ratio it later selects, without changing the total authorized shares or par value.
The main goal is to lift the share price to satisfy Nasdaq’s $1.00 minimum bid requirement and maintain the current listing. As of January 22, 2026, ClearSign had 53,615,991 common shares outstanding, with 87,500,000 authorized. The proxy explains potential benefits (improved marketability and institutional interest) and risks, including possible reduced liquidity, lower market capitalization, and no assurance of regaining or maintaining Nasdaq compliance.
ClearSign Technologies Corporation furnished an update with preliminary, unaudited financial information for the fourth quarter and full fiscal year ended December 31, 2025. The company disclosed this information through a press release dated January 7, 2026. Management prepared the preliminary data, and the independent registered public accounting firm, BPM CPA LLP, has not audited, reviewed, compiled, or performed any procedures on these figures and therefore provides no assurance on them.
The disclosure is being made under Items 2.02 and 7.01 and is expressly designated as “furnished” rather than “filed,” meaning it is not subject to certain liability provisions of the Exchange Act and will only be incorporated into other securities filings if specifically referenced. The press release is included as Exhibit 99.1 to the report.
ClearSign Technologies Corporation reported that it released its financial results for the quarter ended September 30, 2025. On November 19, 2025, the company issued a press release detailing these results and held a conference call to discuss the financial performance and other business information. The press release and the call transcript are provided as Exhibits 99.1 and 99.2 to this Form 8-K and are furnished, rather than filed, which limits their use for certain liability purposes under the Exchange Act.
ClearSign Technologies Corporation reported governance and compensation updates approved on November 11, 2025. The Board adopted Amended and Restated Bylaws that set director elections to require a majority of votes cast, except when there are more nominees than seats, in which case a plurality voting standard will apply. The bylaws also tighten procedures for stockholder proposals and director nominations, including a longer advance notice window and new requirements for proof of continuous beneficial ownership and a commitment to hold shares through the annual meeting.
Separately, the Human Capital and Compensation Committee approved revised forms of stock option, restricted stock unit, and restricted stock award agreements for future grants under the 2021 Equity Incentive Plan. These agreements now apply Delaware governing law and Delaware courts for jurisdiction and venue, aligning them with the company’s state of incorporation.
ClearSign Technologies filed its Q3 2025 report, showing lower activity and continued operating losses. Revenue was $1.03 million with gross profit of $0.37 million, while the company posted a net loss of $1.43 million for the quarter. For the nine months, revenue was $1.56 million and net loss was $5.19 million.
Cash and cash equivalents were $10.49 million, and working capital totaled $8.17 million as of September 30, 2025. Contract liabilities rose to $1.15 million, reflecting customer prepayments on projects not yet completed. Stockholders’ equity was $9.08 million with no debt.
The company established a new at-the-market program of up to $10.39 million and noted Nasdaq’s extension to regain the $1.00 minimum bid price by March 30, 2026. Operating expenses increased year over year, driven mainly by non-cash RSU vesting tied to board departures and higher legal/audit costs, partially offset by prior China-related accruals not repeating.
ClearSign Technologies (CLIR) reported a director equity transaction. On 10/01/2025, a non‑executive director acquired 24,621 restricted stock units (RSUs) at $0.00 under the company’s 2021 Equity Incentive Plan as compensation for the quarter ending December 31, 2025.
The RSUs vest upon the first to occur of a change in control, disability, death, or separation from service. After this grant, the reporting person directly beneficially owned 70,266 derivative securities.
ClearSign Technologies (CLIR) reported a director equity grant on Form 4. On 10/01/2025, the reporting person acquired 26,830 restricted stock units (RSUs) at $0.00 as compensation for non‑executive director service for the quarter ending December 31, 2025. Each RSU represents the right to receive one share of common stock or the cash equivalent.
Following the transaction, 120,469 derivative securities were beneficially owned on a direct basis. The RSUs will vest upon the first to occur of a Change in Control, the reporting person’s Disability, death, or separation from service.
ClearSign Technologies Corporation received a second notice from Nasdaq on September 30, 2025 granting a 180-day extension, until March 30, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company previously fell out of compliance after its stock traded below $1.00 for 30 consecutive business days ending March 31, 2025. ClearSign told Nasdaq it intends to regain compliance, including potentially effecting a reverse stock split if needed. If the closing bid price reaches at least $1.00 for 10 consecutive business days before the deadline, the company will be back in compliance. If it fails to do so, its common stock may be delisted, though ClearSign could appeal any delisting determination. For now, the extension has no immediate effect on the listing or trading of its shares, which continue to trade on Nasdaq under the symbol CLIR.
ClearSign Technologies Corporation reported changes to its board structure that restore compliance with Nasdaq’s director and audit committee independence rules. After two independent directors resigned in early August, the company had fallen out of compliance with Nasdaq Listing Rule 5605(b)(1) and 5605(c)(2)(A). On August 26, 2025, the board determined that director Anthony DiGiandomenico qualifies as an independent director under Nasdaq rules and appointed him to the Audit and Risk Committee. The board also named independent director G. Todd Silva as chair of the Audit Committee and designated him as the committee’s audit committee financial expert. Nasdaq subsequently confirmed on August 28, 2025 that ClearSign had regained compliance, although the board still plans to fill one remaining vacancy.
ClearSign Technologies (CLIR) filed a prospectus supplement describing an offering that would result in 57,693,504 shares of common stock outstanding assuming full exercise of the Warrants. The filing confirms the company’s common stock trades on Nasdaq under the symbol CLIR. The prospectus lists various dilutive instruments: restricted stock units (~1,077,000 shares), outstanding stock options (~2,397,000 shares at a weighted-average exercise price of $2.03), outside-plan options (~491,000 shares at $1.53), reserved plan shares (~1,692,000), consultant plan reserve (~278,000), underwriter warrants (425,109 shares at $1.1375), redeemable warrants (15,147,606 shares at $1.05), pre-funded warrants (2,795,395 at $0.0001), and placement agent warrants (432,432 at $1.1375). The prospectus references net tangible book value per share as of June 30, 2025 but does not state a figure in the provided excerpt. Two dates, May 15, 2025 and August 14, 2025, appear in the text.